Can-Fite BioPharma completes RA Phase III study of lead drug applicant CF101 Can-Fite BioPharma Ltd.

The scholarly study primary end point will be ACR 20 response at Week 12. The A3 adenosine receptor biomarker will end up being evaluated prior to treatment and its own correlation to patients' response to the drug will be analyzed upon study conclusion. Related StoriesAbbVie programs to advance ABT-494 to Phase 3 studies in rheumatoid arthritisNo progression in joint harm in 84 percent of psoriatic arthritis patientsAbbVie reports excellent results from ABT-494 Phase 2 clinical trials in sufferers with rheumatoid arthritisThe Phase III design is based on positive data received from the company's completed Phase IIb study where CF101 was administered as a monotherapy. The Stage IIb research was a 12-week multicenter, randomized, double-blind, placebo-controlled, parallel-group research involving 79 sufferers with energetic RA.Within the Madabhushi lab, postdoctoral experts Jon Whitney and Yu Zhou and PhD college student Xiangxue Wang will work on the project. They’ll build on the ongoing work of George Lee, research assistant professor in biomedical engineering at Case Western Reserve, who was awarded a 3-season recently, $245,000 NIH grant to mix genomics and proteomic with digital pathology pictures of prostate malignancy. Lee, working with assistance from Madabhushi and Sanjay Gupta, MD, a professor of urology at Case Western College of Medicine, will develop machine learning tools for merging molecular and image features for improved prediction of aggressive prostate cancers.